Cenplacel(Celgene Corporation)

N/A

Report date: 2024/03/21 16:12:04

Base Information

Drug NameCenplacel(Celgene Corporation)
Drug Alias NamePlacental-derived adherent cells intramuscularPDAC cellsPDA-002
ClassificationCell and gene therapy > Cell therapy > Source of cells > Placenta-derivedCell and gene therapy > Cell therapy
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsDiabetic FootPeripheral Arterial DiseaseDiabetic Nephropathies +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesCelularity Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Facioscapulohumeral
Inactive IndicationsDiabetic FootPeripheral Arterial DiseaseDiabetic Nephropathies +[4] 

Other Information

ATC CodeN/A
Related LinksN/A